Basic scienceHigh expression of the Met receptor in prostate cancer metastasis to bone☆
Section snippets
Patients
All men underwent radical prostatectomy at the New York Presbyterian Hospital. The operating urologist followed up patients with physical examinations and yearly PSA measurements. Patients without recurrence had a minimum of 5 years of follow-up. No patient received neoadjuvant hormonal therapy or postoperative therapy before the study endpoint, which was a documented biochemical recurrence. The recurrence was defined as two consecutive serum PSA values greater than 0.2 ng/mL. Approval from the
Met expression in normal prostate epithelium
Our data confirm the previous reports that Met is highly expressed in prostate basal cells and in atrophic prostate epithelial cells. The secretory cells were negative by immunohistochemistry for Met membrane expression. The urothelial cells expressed high levels of Met (Fig. 1A). At the transition from urothelium to prostate epithelium, Met staining became confined to the basal cell layer of the prostatic ducts.
Met expression in locally invasive prostate cancer
Met expression was analyzed in a cohort of 90 patients who underwent radical
Comment
The question of whether Met expression correlates with progression to metastatic disease in prostate cancer has not been previously examined. We assembled a cohort of GS 6 and 7 prostate cancers and used serum PSA measurements as a surrogate marker for the detection of tumor progression/metastasis. In this study, we observed no correlation between Met staining and tumor recurrence, although it is conceivable that a different endpoint (eg, survival) or a cohort of patients with high-grade cancer
Conclusions
The immunohistochemical evidence of Met expression in bone metastasis and bone stromal cells justifies the development of Met-directed imaging and therapeutic agents, because therapeutic strategies that attack the tumor, as well as the bone, are more powerful and promising than those that target the tumor alone.
Acknowledgements
To Brian Hutchinson for immunohistochemical staining and Dr. Peter Schlegel for referring patients with recurrent prostate cancer.
References (15)
- et al.
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor
Am J Pathol
(2001) - et al.
c-Met proto-oncogene expression in benign and malignant human prostate tissues
J Urol
(1995) - et al.
Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers
Cancer Lett
(1999) - et al.
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
Cytokine Growth Factor Rev
(2002) - et al.
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens
Urology
(1999) The biology of hormone refractory prostate cancerwhy does it develop?
Urol Clin North Am
(1999)- et al.
Stem cell features of benign and malignant prostate epithelial cells
J Urol
(1998)
Cited by (168)
A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
2021, Clinical Genitourinary CancerThe spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination
2021, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :The pathways involved in bony metastasis have yet to fully elucidated; VEGF and MET receptors have been shown to be expressed on osteoblasts and osteoclasts, regulating their proliferation, migration, and survival. The tyrosine-kinase inhibitor cabozantinib, with activity toward VEGF and MET has been postulated as a mediator of this process, and indeed, the clinical activity of cabozantinib in patients with bone metastases from RCC has been confirmed in a phase III trial [7–9]. One important way to understand this process, and whether there exist clinically meaningful bone-specific processes driving metastasis, is to differentiate the degree to which bony metastasis is a random stochastic event based on relative blood flow patterns, vs. driven by homing or organ-specific colonization ability.
Therapies of bone metastases in castration-resistant prostate cancer
2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedsidec-Met expression in renal cell carcinoma with bone metastases
2020, Journal of Bone Oncology
- ☆
This study was supported by the SPORE in Prostate Cancer, P50 CA 92629.